NEWS

FOR IMMEDIATE RELEASE   STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison (919) 903-2057 kevin.scorsone@ncoda.org www.ncoda.org Federal Trade Commission Seeking Information on How PBMs Impact Practices and Patients On February 24, 2022, the Federal Trade Commission (FTC) announced that they are soliciting public input on the […]

FOR IMMEDIATE RELEASE STATEMENT FROM NCODA’S LEGISLATIVE & POLICY ADVISORY COMMITTEE Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org PBM REFORM BILL MAKING STRIDES IN VIRGINIA HOUSE OF REPRESENTATIVES          In recent weeks, NCODA has been closely following and applauding PBM reform along with new provisions regarding patient copayments. […]

February 18, 2022   FOR IMMEDIATE RELEASE   STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org OVERWHELMING CONSENSUS IN HOUSE PUTS PBM BILL ON DOORSTEP A Comprehensive PBM Reform Bill is on the Desk of Michigan Gov. Gretchen Whitmer Awaiting […]

Contact: Katie Edmiston | Marketing Manager NCODA, Inc. (813) 843-1629 Katie.Edmiston@ncoda.org   February 17, 2022   NCODA Stands United with Biden Administration on Cancer Moonshot   (CAZENOVIA, NY) – NCODA has always been committed to empowering the medically integrated oncology team to deliver positive, patient-centered outcomes by providing leadership, expertise, quality standards and best practices. […]

Written by: Eric Dallara, RPh, New England Cancer Specialist Download Here Description:  Diarrhea is the main toxicity of neratinib treatment occurring in 95% of patients in the ExteNET trial on the neratinib arm in which antidiarrheal prophylaxis was not protocol specified.1 Various prevention and treatment strategies for diarrhea have been studied and will be discussed […]

Beginning February 14, 2022, there is a new NDC number for TIBSOVO® (72694-0617-60)*, the old NDC number was 71334-0100-01. SERVIER has new product packaging. The product itself remains the same. Listed below are pictures of the updated product packaging and ordering information. Updated Product Ordering Information: Description Strength/Size Supplier New NDC # TIBSOVO® (ivosidenib tablets) 250 mg tablet […]

Written by: Brandy Persson, PharmD, BCPS, BCOP and Rebecca Fanning, PharmD, BCPS, Cone Health Download Here Description: Fam-trastuzumab deruxtecan-nxki is indicated for the treatment of: Adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer previously treated with two or more anti-HER2-based regimens.1,2 This indication is under accelerated approval based […]

Written by: Joshua Nubla, PharmD, NCODA Download Here Description: The purpose of this PQI is to discuss the overall management of durvalumab and immune-mediated adverse events in the treatment of Stage III unresectable NSCLC and first-line extensive stage small cell lung cancer. Background: Durvalumab is a PD-L1 blocking monoclonal antibody and immune checkpoint inhibitor indicated […]

Written by: Linda Frisk, PharmD, Ironwood Cancer and Research Centers Download Here Description: The purpose of this PQI is to provide background on PI3K inhibition and review clinical considerations for duvelisib therapy in order to optimize outcomes for cancer patients as well as identifying the patients with malignant lymphoma who may be candidates for duvelisib. […]

Written by: Jeremiah Moore, PharmD, University of Rochester Medical Center Download Here Description: This PQI will provide background on the novel medication selinexor for patients with multiple myeloma (MM) who have received at least one prior therapy, relapsed, refractory multiple myeloma (RR-MM), and relapsed, refractory diffuse large b-cell lymphoma (RR-DLBCL) and discuss effective practices to […]

Written by: Jon Suyko, PharmD, BCPS UCHealth Highlands Ranch Download Here  Description: The purpose of this PQI is to discuss the option of using isatuximab-irfc (Sarclisa) for multiple myeloma patients who have been refractory to one to three prior lines of therapy or have had two prior treatment therapies including treatment with lenalidomide and a […]

Written By: Pedro C. Barata, MD, Tulane University DOWNLOAD HERE   Description: The purpose of this PQI is to review the clinical considerations around the use of tivozanib (Fotivda®) for patients with relapse or refractory advanced renal cell carcinoma.   Background: Tivozanib is a small molecule that inhibits the phosphorylation of vascular endothelial growth factor […]